Showing results (751-760 of 1,395) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|February 17, 2022
Acral Lentiginous Melanoma Harboring a ROS1 Gene Fusion With Clinical Response to EntrectinibKasey L Couts, Caroline E McCoach, Danielle Murphy, et al.
JCO Precision Oncology|February 17, 2022
Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast CancerAmelie De Gregorio, Thomas W P Friedl, Jens Huober, et al.
JCO Precision Oncology|February 21, 2022
Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA SubstudyYoshiaki Nakamura, Wataru Okamoto, Tadamichi Denda, et al.
JCO Precision Oncology|January 27, 2022
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung CancersAlexander Drilon, Daniel S W Tan, Ulrik N Lassen, et al.
JCO Precision Oncology|February 1, 2022
Correlation Between Tumor-Specific Mutated and Methylated DNA in Colorectal CancerCaroline Brenner Thomsen, Rikke F Andersen, Jan Lindebjerg, et al.
JCO Precision Oncology|February 1, 2022
Primer on Hereditary Cancer Predisposition Genes Included Within Somatic Next-Generation Sequencing PanelsZade Akras, Brandon Bungo, Brandie H Leach, et al.
JCO Precision Oncology|February 1, 2022
Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA AnalysisVincenza Conteduca, Emanuela Scarpi, Federica Matteucci, et al.
JCO Precision Oncology|February 1, 2022
Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy-Resistant Early Breast CancersJane Bayani, Elizabeth N Kornaga, Cheryl Crozier, et al.
JCO Precision Oncology|February 1, 2022
Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic ModelNathan A Pennell, Alex Mutebi, Zheng-Yi Zhou, et al.
JCO Precision Oncology|February 1, 2022
Comutation of PIK3CA and TP53 in Residual Disease After Preoperative Anti-HER2 Therapy in ERBB2 (HER2)-Amplified Early Breast CancerFrankie Ann Holmes, Maren K Levin, Ying Cao, et al.
Pageof 140